These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Detection and Assessment of α-Synuclein Oligomers in the Urine of Parkinson's Disease Patients. Nam D; Lee JY; Lee M; Kim J; Seol W; Son I; Ho DH J Parkinsons Dis; 2020; 10(3):981-991. PubMed ID: 32444560 [TBL] [Abstract][Full Text] [Related]
6. A FRET-based aptasensor for the detection of α-synuclein oligomers as biomarkers of Parkinson's disease. Saedi Z; Nikkhah M Anal Methods; 2022 Aug; 14(30):2937-2944. PubMed ID: 35861142 [TBL] [Abstract][Full Text] [Related]
7. Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease. Wang X; Yu S; Li F; Feng T Neurosci Lett; 2015 Jul; 599():115-9. PubMed ID: 25998655 [TBL] [Abstract][Full Text] [Related]
8. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays. Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145 [TBL] [Abstract][Full Text] [Related]
9. Enhanced Plasmonic Biosensor Utilizing Paired Antibody and Label-Free Fe Mandala SHS; Liu TJ; Chen CM; Liu KK; Januar M; Chang YF; Lai CS; Chang KH; Liu KC Biosensors (Basel); 2021 Oct; 11(10):. PubMed ID: 34677358 [TBL] [Abstract][Full Text] [Related]
10. Antibodies against alpha-synuclein: tools and therapies. Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836 [TBL] [Abstract][Full Text] [Related]
11. Analysis of anticoagulants for blood-based quantitation of amyloid β oligomers in the sFIDA assay. Kravchenko K; Kulawik A; Hülsemann M; Kühbach K; Zafiu C; Herrmann Y; Linnartz C; Peters L; Bujnicki T; Willbold J; Bannach O; Willbold D Biol Chem; 2017 Apr; 398(4):465-475. PubMed ID: 27811340 [TBL] [Abstract][Full Text] [Related]
12. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596 [TBL] [Abstract][Full Text] [Related]
13. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. Vivacqua G; Latorre A; Suppa A; Nardi M; Pietracupa S; Mancinelli R; Fabbrini G; Colosimo C; Gaudio E; Berardelli A PLoS One; 2016; 11(3):e0151156. PubMed ID: 27011009 [TBL] [Abstract][Full Text] [Related]
14. Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson's disease. Hu Q; Uversky VN; Huang M; Kang H; Xu F; Liu X; Lian L; Liang Q; Jiang H; Liu A; Zhang C; Pan-Montojo F; Zhu S Biochim Biophys Acta; 2016 Oct; 1862(10):1883-90. PubMed ID: 27425033 [TBL] [Abstract][Full Text] [Related]
15. A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson's disease. Wang R; Pang SC; Li JY; Li CL; Liu JM; Wang YM; Chen ML; Li YB Anal Bioanal Chem; 2023 Apr; 415(9):1589-1605. PubMed ID: 36688984 [TBL] [Abstract][Full Text] [Related]
16. α-Synuclein in Parkinson's disease and advances in detection. Chen R; Gu X; Wang X Clin Chim Acta; 2022 Apr; 529():76-86. PubMed ID: 35176268 [TBL] [Abstract][Full Text] [Related]
17. [α-Synuclein as Diagnostic Biomarker]. Ono K Brain Nerve; 2020 Feb; 72(2):137-141. PubMed ID: 32036339 [TBL] [Abstract][Full Text] [Related]
18. Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Visanji NP; Marras C; Hazrati LN; Liu LW; Lang AE Mov Disord; 2014 Apr; 29(4):444-50. PubMed ID: 24375496 [TBL] [Abstract][Full Text] [Related]